FAH

Your liver runs a small assembly line that breaks down tyrosine, one of the protein building blocks in everything you eat. The last step on that line depends on a single enzyme. If both copies of the gene that makes this enzyme carry damaging changes, toxic byproducts pile up inside liver and kidney cells, and the result is a rare inherited disease called hereditary tyrosinemia type 1.

Testing the FAH (fumarylacetoacetate hydrolase) gene tells you whether you carry one of these damaging changes. That matters for two groups of people: families with a known case of tyrosinemia type 1, and adults whose liver disease or relatives' history points toward an inherited cause that routine labs have not explained.

What the FAH gene actually does

The FAH gene contains the instructions for making the enzyme fumarylacetoacetate hydrolase. This enzyme finishes the last step in the tyrosine breakdown pathway, splitting a molecule called fumarylacetoacetate into harmless pieces your body can use or get rid of. When the enzyme is missing or broken, fumarylacetoacetate and a related toxin called maleylacetoacetate build up inside cells, especially in the liver and kidneys.

Decades of research have catalogued many different damaging changes in this gene. In one survey of 29 affected patients, a single splicing change called IVS6-1(G>T) accounted for about 70% of altered gene copies. In French Canada, one specific splice mutation is so common it can be screened for across the at-risk population. In Finland, a stop mutation called W262X is the dominant cause. The picture across northern Europe and the Mediterranean is more mixed, with multiple different changes contributing to disease.

Why two faulty copies cause real damage

Hereditary tyrosinemia type 1 is inherited in a recessive pattern, meaning a person needs damaging changes in both copies of the FAH gene for the disease to appear. Carriers of a single faulty copy generally do not show symptoms. When both copies are affected, the toxic backup of fumarylacetoacetate poisons liver cells and kidney tubule cells from infancy onward.

Untreated, the disease progresses to cirrhosis (heavy scarring that stops the liver from working), kidney tubule dysfunction, and a high risk of hepatocellular carcinoma (liver cancer). Even with the first-line drug nitisinone, which blocks an earlier enzyme in the pathway and prevents the toxic buildup, hepatocellular carcinoma can still occur, so strict follow-up after diagnosis is important.

Liver disease and liver cancer risk

The most consequential association is between FAH gene defects and liver damage. Tyrosinemia type 1 causes severe liver dysfunction, cirrhosis, and an elevated lifetime risk of hepatocellular carcinoma. The risk does not vanish even with treatment: hepatocellular carcinoma has been documented in patients on nitisinone, particularly when treatment is started late, which is why long-term liver imaging and tracking of alpha-fetoprotein remain part of care.

One striking feature of this disease is that patches of liver tissue sometimes spontaneously correct one of the faulty gene copies, restoring normal enzyme activity in those cells. This self-correction was documented in a study of 18 patients and a separate case series of 4 patients. In a study of 26 affected livers, frequent self-correction was linked to milder clinical disease, suggesting the corrected tissue offers some protection. It also means a liver biopsy showing normal enzyme in places can be misleading if interpreted without genetic confirmation.

Kidney involvement

The same toxic buildup damages cells in the kidney tubules, the small tubes that fine-tune what gets reabsorbed from urine. Affected children can develop a tubular dysfunction that wastes phosphate and other nutrients, contributing to rickets-like bone disease. Original biochemical work from the 1970s pinned the kidney findings on the same enzyme defect as the liver disease.

Neurological crises

Toxic intermediates also disrupt heme synthesis, the chemistry your body uses to build the oxygen-carrying part of red blood cells. The result can be acute neurological crises that look similar to porphyria attacks, with pain, weakness, and in rare cases an abnormal water-handling pattern called SIADH (a condition where the body holds onto too much water, causing sodium to drop). These crises are most common during metabolic decompensation and are part of why early diagnosis and consistent treatment matter.

Neurocognitive outcomes

Even with treatment, the disease can leave a cognitive footprint. A study of 38 treated patients compared with healthy controls found poorer IQ, executive function, and social cognition scores. The takeaway is that IQ screening alone is not enough to monitor brain function in this population, and broader cognitive testing is warranted over time.

Genotype does not perfectly predict phenotype

Several studies looking at FAH gene changes in affected patients have reached the same conclusion: the specific mutation a person carries does not tightly predict how severe their disease will be. A study of 13 patients found no strict link between genotype and phenotype. Studies in northern European and Mediterranean populations reached the same conclusion. This means a positive test tells you the diagnosis but not the trajectory, which is one reason serial monitoring matters more than the genetic result alone.

Atypical and silent presentations

A case series of 3 adults with liver cirrhosis and hepatocellular carcinoma found a novel FAH gene change in people who had normal tyrosine and normal succinylacetone (the chemical newborn screening relies on). In other words, the standard biochemical screen missed them, and only targeted gene sequencing made the diagnosis. If you have unexplained chronic liver disease or hepatocellular carcinoma in your family and routine workups have not produced an answer, FAH gene testing is reasonable to pursue.

How FAH testing fits with newborn screening

Most cases are first picked up not by FAH gene testing but by newborn screening that measures succinylacetone, a chemical that builds up when the enzyme does not work. In the Netherlands, a review of 693,821 newborns confirmed that adding succinylacetone to standard screening improves how often a positive result genuinely reflects disease. A separate systematic review concluded the approach is promising, with further long-term follow-up needed.

Screening is not perfect. A reported false-negative case described a child whose mild FAH variant produced low succinylacetone, slipping past the screen. The complementary role of FAH gene testing is to confirm a positive newborn screen, clarify ambiguous results, identify carriers in families, and diagnose adults whose disease was missed in infancy.

Tracking your trend

A genetic result like FAH does not change over time, so the test itself is run once. What does change, and what serial tracking is for, are the downstream markers of how the disease is affecting your body. If a damaging FAH genotype is confirmed, you and your doctors will follow liver function tests, alpha-fetoprotein, liver imaging, kidney tubule markers, and tyrosine and succinylacetone levels at regular intervals to make sure treatment is working and to catch hepatocellular carcinoma early.

For people in affected families, periodic checks of these downstream markers are at least annual, and more often during the first year after starting treatment or making a dietary change. The genetic test gives you the diagnosis; the trend on the follow-up labs tells you whether your management is on track.

What an unexpected result should prompt

A positive FAH gene test, meaning damaging changes in both copies, calls for prompt evaluation by a metabolic specialist or hepatologist. The standard workup includes measurement of tyrosine and succinylacetone, liver enzymes (ALT, AST, GGT, alkaline phosphatase), synthetic liver function (albumin, prothrombin time), alpha-fetoprotein for liver cancer surveillance, kidney function tests including phosphate handling, and abdominal imaging.

If you carry only one damaging copy, you are a carrier rather than affected. The implication is primarily for family planning: if your partner is also a carrier, each child has a one in four chance of inheriting two damaging copies. Cascade testing of relatives is a standard recommendation when a family-level diagnosis is made.

If the test is ordered to investigate unexplained chronic liver disease in an adult and a damaging FAH genotype is found, treatment with nitisinone plus a low-tyrosine, low-phenylalanine diet is the recognized approach, supervised by a metabolic specialist. Ongoing screening for hepatocellular carcinoma remains essential.

When results can be misleading

Gene tests are generally more stable than biochemical tests, but there are still pitfalls worth knowing about.

• Variants of uncertain significance: not every change in the FAH gene is clearly disease-causing. If your report flags a change that has not been seen before, the interpretation may evolve as databases grow. Reanalysis every few years is reasonable.
• Self-correction in liver tissue: patches of liver can spontaneously revert one of the faulty copies, so a liver biopsy showing enzyme activity in some cells does not mean the genetic diagnosis is wrong. Genetic testing remains the reference.
• Atypical biochemical presentations: rare variants can produce normal tyrosine and normal succinylacetone, masking the diagnosis on standard biochemical screens. Genetic confirmation matters most when clinical suspicion is high but biochemistry looks normal.
• Coverage limits of the assay: different labs sequence different parts of the gene and may or may not pick up large deletions or deep intronic changes. A negative test from a limited panel does not always rule out an FAH-related cause if suspicion is high.